Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC. Design: Retrospective study of consecutive pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JTO Clinical and Research Reports
Subjects:
Pralsetinib
Lung Cancer
RET
Second-Line
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001139
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324001139

Similar Items